trial

Linagliptin in Schizophrenia Patients

NCTId NCT01943019
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Terminated
Enrollment 1 (actual)
Sponsored by Monash University
Primary completion 2018-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Terminated
Enrollment
1 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2013-08
Primary completion
2018-07
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Linagliptin

Sponsors

Monash UniversityLead Sponsor
Universiti Kebangsaan Malaysia Medical CentreCollaborator

Investigators

1
Maniam ThambuPrincipal Investigator

Sites

1 total
Bandar Tun Razak, Malaysia

Facts & assertions

4 sourced
Enrollment
1
Phase
PHASE1
Primary Completion Date
2018-07
Status
TERMINATED
relationships
The graph out of here
drug
Linagliptin
drug
lead_sponsor
Monash University
company
collaborator
Universiti Kebangsaan Malaysia Medical Centre
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Maniam Thambu
person